Prognostic value of stage grouping and TNM descriptors in lung cancer

Chest

Volumn 117, Issue 5, 2000, Pages 1247-1255

  Buccheri, Gianfranco ^a,b   Ferrigno, Domenico ^a  

^a S Croce e Carle City Hospital   (Italy)

^b S CROCE E CARLE HOSPITAL   (Italy)

Author keywords

Classification; Lung neoplasm; Multivariate analysis; Neoplasm staging; Non small cell lung cancer; Prognosis

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; LOMUSTINE; METHOTREXATE; MITOMYCIN; NAVELBINE; PROCARBAZINE; VINBLASTINE; VINCRISTINE;

ADULT; AGED; ARTICLE; CANCER CLASSIFICATION; CANCER GRADING; CANCER STAGING; CANCER STATISTICS; CANCER SURVIVAL; FEMALE; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROGNOSIS; RELIABILITY; SURVIVAL TIME;

EID: 0034035234     PISSN: 00123692     EISSN: None     Source Type: Journal    
DOI: 10.1378/chest.117.5.1247     Document Type: Article

References (37)

1. 1 Bülzebruck H, Bopp R, Drings P, et al. New aspects in the staging of lung cancer: prospective validation of the International Union Against Cancer TNM classification. Cancer 1992; 70:1102-1110
2. 2 Chissov VI, Trakhtenberg AK, Frank GA. Classification, and terminology of malignant lung neoplasms (polemic aspects) [in Russian]. Khirurgiia (Mosk) 1995; 1:14-17
3. 3 Jett JR. What's new in staging of lung cancer [editorial]. Chest 1997; 111:1486-1487
4. 4 Appere DV, Brechot JM, Lebeau B. The TNM classification: critical review [in French]. Rev Mal Respir 1998; 15:323-332
5. 5 Inoue K, Sato M, Fujimura S, et al. Prognostic assessment of 1310 patients with non-small-cell lung cancer who underwent complete resection from 1980 to 1993. J Thorac Cardiovasc Surg 1998; 116: 407-411
6. 6 Mountain CF. Revisions in the International System for Staging Lung Cancer. Chest 1997; 111:1710-1717
7. 7 Mountain CF. A new international staging system for lung cancer. Chest 1986; 89(suppl):225S-233S
8. 8 Naruke T. Results of resected lung cancer based on the new UICC TNM classification, 5th edition [in Japanese]. Jpn J Cancer Chemother 1997; 24:2289-2295
9. 9 Leong SS, Lima CMR, Sherman CA, et al. The 1997 international staging system for non-small cell lung cancer: have all the issues been addressed? Chest 1999; 115:242-248
10. 10 Buccheri G, Ferrigno D. The tissue polypeptide antigen serum test in the preoperative evaluation of non-small cell lung cancer: diagnostic yield and comparison with conventional staging methods. Chest 1995; 107:471-476
11. 11 Buccheri G, Ferrigno D, Vola F. Carcinoembryonic antigen (CFA), tissue polyptide antigen (TPA), and other prognostic indicators in the squamous cell carcinoma of the lung. Lung Cancer 1993; 10:21-33
12. 12 Buccheri G, Vola F, Ferrigno D, et al. Yield of whole body GA-67 scintigraphy in the staging of lung cancer. Tumori 1989; 75:38-42
13. 13 Buccheri G, Biggi A, Ferrigno D, et al. Imaging lung cancer by scintigraphy with indium-111 labeled F(ab')2 fragments of the anticarcinoembryonic antigen monoclonal antibody FO23C5. Cancer 1992; 70:749-759
14. 14 Buccheri G, Biggi A, Ferrigno D, et al. Anti-CFA immunoscintigraphy and computed tomographic scanning in the preoperative evaluation of mediastinal lymph nodes in lung cancer. Thorax 1996; 51:359-363
15. 15 Buccheri G. Chemotherapy and survival in non-small cell lung cancer: the old "vexata questio" [editorial]. Chest 1991; 99:1328-1329
16. 16 Kaplan EL, Meier F. Non-parametric estimation from incomplete observations. J Am Stat Assoc 1958; 58:457-481
17. 17 Peto R, Pike MC, Armitage P. Design and analysis of randomized clinical trials requiring prolonged observation of each patient: II. Analysis and examples. Br J Cancer 1977; 35:1-39
18. 18 Cox DR. Regression models and life tables. J R Stat Soc 1972; 34:187-220
19. 19 Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, ed. Evaluation of chemotherapeutic agents. New York, NY: Columbia University Press, 1949; 199-205
20. 20 Johnson BE. Biologic and molecular prognostic factors: impact on treatment of patients with non-small cell lung cancer. Chest 1995; 107(suppl):287S-290S
21. 21 Mountain CF. New prognostic factors in lung cancer: biologic prophets of cancer cell aggression. Chest 1995; 108:246-254
22. 22 Buccheri G, Ferrigno D. Prognostic factors in lung cancer: tables and comments. Eur Respir J 1994; 7:1350-1364
23. 23 Usuda K, Saito Y, Sato M, et al. Assessment of a new TNM classification produced by UICC for resected lung cancer with intrapulmonary satellite tumor(s) [in Japanese]. Nippon Kyobu Geka Gakkai Zasshi 1996; 44:629-633
24. 24 Yano M, Arai T, Inagaki K, et al. Intrapulmonary satellite nodule of lung cancer as a T factor. Chest 1998; 114:1305-1308
25. 25 Mizushima Y, Noto H, Kusajima Y, et al. Results of pneumonectomy for non-small cell lung cancer: appropriateness of the new TNM staging system. Oncol Rep 1998; 5:437-440
26. 26 Drings P, Bülzebruck H, Vogt-Moykopf I. Prognostic impact of the new 5th edition of the TNM classification for lung cancer [abstract]. Lung Cancer 1997; 18(suppl):215
27. 27 Ginsberg R, Cox J, Green M, et al. Staging classification committee. Lung Cancer 1997; 17(suppl):S11-S13
28. 28 Rami-Porta R. Reflections on the revision in the International System for Staging Lung Cancer [letter]. Chest 1998; 113: 1728-1729
29. 29 Margolis ML. Lung cancer staging: a proposal [letter]. Chest 1998; 114:660-661
30. 30 World Health Organization. International histological classification of tumours. Berlin, Germany: Springer-Verlag, 1991
31. 31 Buccheri G, Ferrigno D, Vola F, et al. Combination of chemotherapy with methotrexate, Adriamycin, cyclophosphamide, and CCNU (MACC) for non-small cell lung cancer: 4-year experience with 92 patients. Oncology 1989; 46:212-216
32. 32 Buccheri G, Ferrigno D, Curcio A, et al. Continuation of chemotherapy versus supportive care alone in patients with inoperable non-small cell lung cancer after two or three cycles of MACC. Cancer 1989; 63:428-432
33. 33 Buccheri G, Ferrigno D, Rosso A, et al. Further evidence in favor of chemotherapy for inoperable non-small cell lung cancer. Lung Cancer 1990; 6:87-98
34. 34 Buccheri G, Ferrigno D. A randomised trial of MACC chemotherapy with or without lonidamine in advanced non-small cell lung cancer: Cuneo Lung Cancer Study Group. Eur J Cancer 1994; 30A:1424-1431
35. 35 Buccheri G, Ferrigno D. Efficacy of platinum-based regimes in non-small cell lung cancer: a negative report from the Cuneo Lung Cancer Study Group. Lung Cancer 1997; 18: 57-70
36. 36 Buccheri G, Ferrigno D, Rosso A. A Phase II study of methotrexate, doxorubicin, cyclophosphamide, and lomustine chemotherapy and lonidamine in advanced non-small cell lung cancer. Cancer 1993; 72:1564-1572
37. 37 Ferrigno D, Buccheri G. Is the MVP regimen less active than previously described?: results of a phase II study in advanced non-small cell lung cancer Acta Oncol 1996; 35:435-439